Product Images Donepezil Hydrochloride
View Photos of Packaging, Labels & Appearance
- Figure 1. Time-course of the Change from Baseline in ADAS-cog Score for Patients Completing 24 Weeks of Treatment. - donepezil fig1
- Figure 10. Cumulative Percentage of Patients Completing 6 Months of Double-blind Treatment with Particular Changes from Baseline in ADCS-ADL-Severe Scores. - donepezil fig10
- Figure 11. Time-course of the Change from Baseline in SIB Score for Patients Completing 24 Weeks of Treatment. - donepezil fig11
- Figure 12. Cumulative Percentage of Patients Completing 24 Weeks of Double-blind Treatment with Specified Changes from Baseline SIB Scores. - donepezil fig12
- Figure 13. Frequency Distribution of CIBIC-plus Scores at Week 24. - donepezil fig13
- Figure 2. Cumulative Percentage of Patients Completing 24 Weeks of Double-blind Treatment with Specified Changes from Baseline ADAS-cog Scores. The Percentages of Randomized Patients who Completed the Study were: Placebo 80%, 5 mg/day 85%, and 10 mg/day 68%. - donepezil fig2
- Figure 3. Frequency Distribution of CIBIC-plus Scores at Week 24. - donepezil fig3
- Figure 4. Time-course of the Change from Baseline in ADAS-cog Score for Patients Completing the 15-week Study. - donepezil fig4
- Figure 5. Cumulative Percentage of Patients with Specified Changes from Baseline ADAS-cog Scores. The Percentages of Randomized Patients Within Each Treatment Group Who Completed the Study Were: Placebo 93%, 5 mg/day 90%, and 10 mg/day 82%. - donepezil fig5
- Figure 6. Frequency Distribution of CIBIC-plus Scores at Week 12. - donepezil fig6
- Figure 7. Time Course of the Change from Baseline in SIB Score for Patients Completing 6 Months of Treatment. - donepezil fig7
- Figure 8. Cumulative Percentage of Patients Completing 6 Months of Double-blind Treatment with Particular Changes from Baseline in SIB Scores. - donepezil fig8
- Figure 9. Time Course of the Change from Baseline in ADCS-ADL-Severe Score for Patients Completing 6 Months of Treatment. - donepezil fig9
- Chemical Structure - donepezil str
- Label - lbl713352093
Product Label Images
The following 15 images provide visual information about the product associated with Donepezil Hydrochloride NDC 71335-2093 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1. Time-course of the Change from Baseline in ADAS-cog Score for Patients Completing 24 Weeks of Treatment. - donepezil fig1
Figure 10. Cumulative Percentage of Patients Completing 6 Months of Double-blind Treatment with Particular Changes from Baseline in ADCS-ADL-Severe Scores. - donepezil fig10
This text appears to be a graph showing the cumulative percentage of patients and their change in ADCS-ADL scores from baseline while taking Donepezil Hydrochloride 10 mg/day compared to the placebo. The graph displays a 100% cumulative percentage of patients with the horizontal axis showing the change in ADCS-ADL scores, ranging from -10 to 5. The Donepezil Hydrochloride 10 mg/day line is represented by "—e—" and the placebo line is represented by "—o—". However, without further context, it is difficult to provide a more specific description of what the graph is depicting.*
Figure 11. Time-course of the Change from Baseline in SIB Score for Patients Completing 24 Weeks of Treatment. - donepezil fig11
Figure 12. Cumulative Percentage of Patients Completing 24 Weeks of Double-blind Treatment with Specified Changes from Baseline SIB Scores. - donepezil fig12
Figure 13. Frequency Distribution of CIBIC-plus Scores at Week 24. - donepezil fig13
Figure 2. Cumulative Percentage of Patients Completing 24 Weeks of Double-blind Treatment with Specified Changes from Baseline ADAS-cog Scores. The Percentages of Randomized Patients who Completed the Study were: Placebo 80%, 5 mg/day 85%, and 10 mg/day 68%. - donepezil fig2
Figure 3. Frequency Distribution of CIBIC-plus Scores at Week 24. - donepezil fig3
Figure 4. Time-course of the Change from Baseline in ADAS-cog Score for Patients Completing the 15-week Study. - donepezil fig4
Figure 5. Cumulative Percentage of Patients with Specified Changes from Baseline ADAS-cog Scores. The Percentages of Randomized Patients Within Each Treatment Group Who Completed the Study Were: Placebo 93%, 5 mg/day 90%, and 10 mg/day 82%. - donepezil fig5
Figure 6. Frequency Distribution of CIBIC-plus Scores at Week 12. - donepezil fig6
This appears to be a table showing the percentage of patients who improved or worsened while taking Donepezil Hydrochloride 10mg/day or 5mg/day, compared to a placebo. The patients' improvement is measured by the CIBIC-plus Rating. The table includes different levels of improvement (Moderately, Markedly, Minimally) and worsening, as well as a category for "No Change."*
Figure 7. Time Course of the Change from Baseline in SIB Score for Patients Completing 6 Months of Treatment. - donepezil fig7
This is a table showing the mean change from baseline in SIB scores after a 3-month drug treatment with either Donepezil Hydrochloride 10 mg/day or placebo. It suggests that there was clinical improvement observed in the Donepezil Hydrochloride group compared to the placebo group.*
Figure 8. Cumulative Percentage of Patients Completing 6 Months of Double-blind Treatment with Particular Changes from Baseline in SIB Scores. - donepezil fig8
The text describes a chart showing the cumulative percentage of patients who took a medicine (Donepazil Hydrochloride 10mg/day) versus a placebo. The chart also shows the SIB (Severe Impairment Battery) change from baseline. There are percentages shown on the chart ranging from 5 to 100 and time increments of 15, 30, 45, 50, and 75.*
Figure 9. Time Course of the Change from Baseline in ADCS-ADL-Severe Score for Patients Completing 6 Months of Treatment. - donepezil fig9
Chemical Structure - donepezil str
Label - lbl713352093
This appears to be a label for a Donepezil medication manufactured by Rising Pharma Holdings Inc. The medication is in the form of a white, round tablet with the marking "X;11" on it. It is intended to treat Dachaged and is comparable to Aricept 5mg tablets. The medication should be stored at room temperature and kept out of reach of children. The label includes information on the quantity, expiration date, NDC number, and manufacturer.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
